Metagenomi Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Metagenomi Therapeutics, Inc. (MGX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $886.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $2.92M, a 1594.77% increase year-over-year.
- Metagenomi Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$2.03M.
- Metagenomi Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$3.19M.
- Metagenomi Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $4.02M.
- Metagenomi Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$1.64M.
- Metagenomi Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$893.00K, a 154.82% decline from fiscal 2023.
- Metagenomi Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $1.63M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $886.00K 10-Q · filed 2026-08-10 | -$2.30M derived: sum of 3 quarters · filed 2026-08-10 | $1.72M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$2.03M 10-Q · filed 2026-05-11 | -$5.22M derived: sum of 2 quarters · filed 2026-05-11 | -$1.20M derived: sum of 3 quarters · filed 2026-05-11 | -$1.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $834.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.01M derived: sum of 3 quarters · filed 2026-08-10 | -$1.64M 10-K · filed 2026-03-05 |
| 2025-09-30 | $4.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.20M derived: sum of 2 quarters · filed 2026-08-10 | $1.55M 10-Q · filed 2025-11-12 | $1.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.48M 10-Q · filed 2026-08-10 | -$2.79M derived: sum of 3 quarters · filed 2026-08-10 | -$3.71M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$2.65M 10-Q · filed 2026-05-11 | -$2.97M derived: sum of 2 quarters · filed 2026-05-11 | -$3.88M derived: sum of 3 quarters · filed 2026-05-11 | -$579.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.23M derived: sum of 2 quarters · filed 2026-03-05 | $2.07M derived: sum of 3 quarters · filed 2026-03-05 | -$893.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$915.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.39M derived: sum of 2 quarters · filed 2025-11-12 | -$575.00K 10-Q · filed 2025-11-12 | $327.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $340.00K 10-Q · filed 2025-08-12 | $1.24M derived: sum of 3 quarters · filed 2025-08-12 | $1.90M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$2.96M 10-Q · filed 2025-05-13 | -$2.06M derived: sum of 2 quarters · filed 2025-05-13 | -$1.41M derived: sum of 3 quarters · filed 2025-05-13 | -$29.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $902.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.56M derived: sum of 2 quarters · filed 2025-03-17 | $2.93M derived: sum of 3 quarters · filed 2025-03-17 | $1.63M 10-K · filed 2025-03-17 |
| 2023-09-30 | $655.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.03M derived: sum of 2 quarters · filed 2024-11-13 | $727.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $72.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$1.30M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |